A Premier Data Driven Drug Discovery Platform for Liver and Metabolic Health
Livergenix is a data-driven drug discovery company focused on the liver, the body’s metabolic centre.
We use precision biology to uncover new drug targets and develop therapies that address metabolic and liver diseases. Our work explores key pathways like PCSK9 and molecules such as Zilebesiran, extending beyond the liver to its connections with the heart and muscle.
The global burden of liver and metabolic diseases is rapidly increasing, driven by rising obesity and diabetes rates worldwide. Metabolic dysfunction-associated steatotic liver disease (MASLD) now affects one-quarter of the global population, leading to severe health complications such as fibrosis, cirrhosis, liver cancer, and cardiovascular disease.
LiverGENIX addresses this urgent health challenge through advanced data analytics, enabling earlier diagnosis, targeted interventions, and improved patient outcomes.
Annual percentage change of cirrhosis from 1990 to 2017. Data from Global Burden of Disease 2017 Cirrhosis Collaborators
A team uniting decades of biotech, venture, and commercial leadership with pioneering expertise in metabolic, liver, and AI-driven research.
We’re always keen to partner with scientists, clinicians, and investors who share our mission to combat liver and metabolic disease.
